REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

28.07.25 22:00 Uhr

Werte in diesem Artikel

NEW YORK, July 28, 2025 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) and certain of its officers.

Bronstein, Gewirtz & Grossman, LLC (PRNewsfoto/Bronstein, Gewirtz & Grossman, LLC)

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/REPL.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated the IGNYTE trial's prospects, despite material issues that Defendants knew or should have known, which ultimately led the FDA to deem the IGNYTE trial inadequate and not well-controlled; and (2) as a result, Defendants' statements regarding Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/REPL. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Replimune you have until September 22, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/repl-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-replimune-group-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302514146.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

In eigener Sache

Übrigens: Replimune Group und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Replimune Group

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Replimune Group

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Replimune Group Inc Registered Shs

Wer­bung

Analysen zu Replimune Group Inc Registered Shs

DatumRatingAnalyst
23.07.2019Replimune Group BuyChardan Capital Markets
08.07.2019Replimune Group BuyH.C. Wainwright & Co.
17.08.2018Replimune Group OutperformBMO Capital Markets
DatumRatingAnalyst
23.07.2019Replimune Group BuyChardan Capital Markets
08.07.2019Replimune Group BuyH.C. Wainwright & Co.
17.08.2018Replimune Group OutperformBMO Capital Markets
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Replimune Group Inc Registered Shs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen